Analytical Data
-
Gene name
PDHa2
- Application
-
Alternative Names
PDHa2；PDHAL；Pyruvate dehydrogenase E1 component subunit alpha. testis-specific form. mitochondrial
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P29803
-
Expression Region
28-388aa
-
AA Sequence
SSN DATFEIKKCD LYLLEEGPPV TTVLTRAEGL KYYRMMLTVR RMELKADQLY KQKFIRGFCH LCDGQEACCV GLEAGINPSD HVITSYRAHG VCYTRGLSVR SILAELTGRR GGCAKGKGGS MHMYTKNFYG GNGIVGAQGP LGAGIALACK YKGNDEICLT LYGDGAANQG QIAEAFNMAA LWKLPCVFIC ENNLYGMGTS TERAAASPDY YKRGNFIPGL KVDGMDVLCV REATKFAANY CRSGKGPILM ELQTYRYHGH SMSDPGVSYR TREEIQEVRS KRDPIIILQD RMVNSKLATV EELKEIGAEV RKEIDDAAQF ATTDPEPHLE ELGHHIYSSD SSFEVRGANP WIKFKSVS
-
Molecular Weight
42.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PDHa2, or Pyruvate Dehydrogenase E2, is a crucial enzyme in the metabolic pathway that facilitates the conversion of pyruvate to acetyl-CoA, linking glycolysis and the citric acid cycle. This enzyme plays a vital role in energy metabolism and is implicated in various metabolic disorders. The study of PDHa2, particularly its recombinant protein form, has gained significant interest in recent years due to its potential therapeutic applications and its involvement in diseases such as diabetes, cancer, and neurodegenerative disorders. The recombinant expression of PDHa2 allows researchers to investigate its structure-function relationships, enzymatic mechanisms, and the effects of post-translational modifications. Moreover, understanding PDHa2’s interactions with other metabolic pathways can provide insights into the regulatory mechanisms of cellular metabolism. By producing and characterizing PDHa2 as a recombinant protein, researchers aim to develop novel strategies for intervention in metabolic diseases and to explore PDHa2 as a biomarker for disease progression. Overall, the research on PDHa2 recombinant protein is crucial not only for advancing our fundamental understanding of metabolism but also for translating these findings into potential clinical applications.
